A leading developer of products for the treatment of multiple sclerosis (MS) – BioMS Medical Corporation (TSE: MS) has been granted clearance by the USFDA of its Investigational New Drug Application (IND) for the initiation of a pivotal phase III clinical trial to investigate the use of MBP8298 as a treatment for patients with secondary progressive MS.
According to Kevin Giese, President and CEO of BioMS Medical:
"The clearance to proceed with a phase III trial in the U.S. is a significant step towards bringing MBP8298 to the worldwide market.
There are approximately 400,000 Americans with MS and close to 50% of patients have secondary progressive MS.
Between the U.S. initiative and the on-going pivotal phase III trial in Canada and Europe, we are successfully executing our global development plan for MBP8298."
MBP8298 makes MS patients tolerant to the body's immune system inappropriate attacks to the myelin coating around the nerves in the brain and spinal column. In a n article recently published in the European Journal of Neurology showed that MBP8298 safely delayed the median time to disease progression for five years in progressive MS patients with HLA-DR2 or HLA-DR4 immune response genes.
Find more details from the press release.
[Photo Credit: Burning Dog]
.jpg)
Comment Preview